Engineered immune cells take on tough blood cancers

NCT ID NCT07162571

Not yet recruiting Disease control Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests a personalized cell therapy called CD19/22 CAR-T cells in 17 adults with relapsed or refractory acute lymphoblastic leukemia or B-cell lymphoma. Patients receive their own immune cells that have been reprogrammed to target and kill cancer cells. The study aims to check safety and whether the treatment can shrink or eliminate the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19/22 CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a new treatment option for adults with hard-to-treat leukemia or lymphoma that has come back or not responded to standard therapy.
What could go wrong: This is an early-phase trial with only 17 participants, so results may not apply broadly. CAR-T therapy can cause severe side effects like cytokine release syndrome or neurological issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell neoplasm lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBKASTIC LEUKEMIA B CELL LYMPHOMA

Contacts and locations

Locations

State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology

Minsk, 220087, Belarus

More trials for these conditions

Other studies related to the condition(s) this trial covers.